Literature DB >> 7655996

Influence of B2 receptor antagonists on bradykinin-induced vasodilation and edema formation in isolated rabbit hindlimbs.

I Breil1, T Koch, S Goldberg, H Neuhof, K van Ackern.   

Abstract

In search of new possibilities to prevent acute inflammatory vascular reaction, we examined the effect of two selective B2 receptor antagonists, CP 0127 ([Bissuccimidohexane (L-Cys6)-1] and HOE 140 (D-Arg[Hyp3, Thi5, D-Tic7, Oic8]BK), on changes in perfusion pressure and on edema formation caused by bradykinin (BK) in the isolated perfused rabbit hindlimbs. CP 0127 and HOE 140 were added to the perfusion fluid 2 min prior to the first BK-administration (5 x 10(-9) mol/l). A second BK-stimulation was performed after 30 minutes. The antagonists were tested in groups of 6 experiments each at concentrations of 10(-6) mol/l, 5 x 10(-9) mol/l and 10(-10) mol/l. CP 0127 was also tested in a concentration of 10(-8) mol/l. The application of BK resulted in an acute decrease of the mean arterial pressure and in a continual edema formation, reflected by an increase of organ weight (controls, n = 6). Pretreatment with CP 0127 as well as with HOE 140 attenuated dose-dependently the BK-induced vasodilation (p < 0.005) and edema formation. The current results indicate that CP 0127 and HOE 140 are able to reduce BK-induced effects on vascular tone and edema formation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7655996     DOI: 10.1007/bf01782261

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  21 in total

1.  Metabolism and characterisation of kinins and Hoe 140 (kinin antagonist) in the synovial fluid of patients with inflammatory joint diseases.

Authors:  A P Bond; G Breipohl; K Worthy; G Campion; P A Dieppe; K D Bhoola
Journal:  Agents Actions Suppl       Date:  1992

Review 2.  New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization.

Authors:  D Regoli; N E Rhaleb; S Dion; G Drapeau
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

3.  Development of bradykinin antagonists: structure-activity relationships for new categories of antagonist sequences.

Authors:  R J Vavrek; J M Stewart
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

4.  Influence of bradykinin on blood pressure regulation of spontaneously hypertensive rats maintained on different sodium intakes.

Authors:  B Waeber; J F Aubert; J Nussberger; R Vavrek; J M Stewart; H R Brunner
Journal:  Clin Exp Pharmacol Physiol       Date:  1987-08       Impact factor: 2.557

Review 5.  Contractile elements in the regulation of macromolecular permeability.

Authors:  F N Miller; D E Sims
Journal:  Fed Proc       Date:  1986-02

6.  Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions.

Authors:  L R Steranka; D C Manning; C J DeHaas; J W Ferkany; S A Borosky; J R Connor; R J Vavrek; J M Stewart; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 7.  The role of endothelium in the responses of vascular smooth muscle to drugs.

Authors:  R F Furchgott
Journal:  Annu Rev Pharmacol Toxicol       Date:  1984       Impact factor: 13.820

8.  Bradykinin-induced oedema formation proceeds from B2 receptor stimulation and is potentiated by concomitantly released prostaglandins.

Authors:  H Neppl; H Neuhof; F Afflerbach; J Llach Puig Neppl; A Berghöfer
Journal:  Acta Physiol Scand       Date:  1991-06

9.  Morphological and physiological correlation of bradykinin-induced macromolecular efflux.

Authors:  E Svensjö; K E Arfors; R M Raymond; G J Grega
Journal:  Am J Physiol       Date:  1979-04

10.  Attenuation of arterial blood pressure fall in endotoxin shock in the rat using the competitive bradykinin antagonist Lys-Lys-[Hyp2, Thi5,8, DPhe7]-Bk (B4148).

Authors:  J Weipert; H Hoffmann; M Siebeck; E T Whalley
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.